文献速递腹部技术与安全MR

定量MR指标识别MASH及纤维化单中心研究

Quantitative MR biomarkers in identifying steatohepatitis and fibrosis associated with metabolic dysfunction associated liver disease-a single center cross-sectional study.
PubMed 文献 · Abdom Radiol (NY) · 2026-07-10

本研究在64例MASLD患者中开展前瞻性横断面研究,46例有肝活检,采用1.5T MR获取MRI-PDFF、T1及IVIM参数。结果显示T1和MRI-PDFF对活检定义的MASH及纤维化MASH具有良好诊断准确性,尤其T1区分纤维化MASH与低风险/无MASH的AUROC为0.851。

要点

  • 怀疑MASH或纤维化MASH时,优先关注T1值与MRI-PDFF,两者均显著升高提示高风险。
  • T1区分纤维化MASH的AUROC最高(0.851),可优先用于纤维化风险分层。
  • IVIM参数在两组中虽有差异,但AUROC未报告,暂不宜单独用于明确诊断。

核心结论

  • MRI T1 mapping与MRI-PDFF对检出活检定义的MASH及纤维化MASH均显示良好诊断准确性。
  • 纤维化MASH组中位T1值(870.48 ms)显著高于低风险/无MASH组(695.10 ms)。
  • 中位MRI-PDFF在纤维化MASH组为20.45%,高于低风险/无MASH组的8.58%。

研究设计与样本

  • 本研究为单中心前瞻性横断面研究,共纳入64例MASLD患者。
  • 共有46例患者接受肝活检并具备可回顾分析的MR数据。
  • 所有MR检查在1.5T设备上完成,获取肝脏MRI-PDFF、T1及IVIM参数。
  • 活检结果依据NASH CRN评分系统进行分组。

关键影像表现/征象

  • MASH组较非MASH组呈现更高的肝脏T1值和MRI-PDFF。
  • 纤维化MASH组较对照组呈现更高的T1值与MRI-PDFF。
  • MASH组较非MASH组D*与f参数显著更低。
  • 纤维化MASH组较低风险/无MASH组D与D*参数更低。

诊断标准与关键数值

  • T1区分MASH与非MASH的AUROC为0.828(95%CI 0.709-0.947)。
  • T1区分纤维化MASH与低风险/无MASH的AUROC为0.851(95%CI 0.742-0.961)。
  • MRI-PDFF区分MASH与非MASH的AUROC为0.808(95%CI 0.657-0.937)。
  • MRI-PDFF区分纤维化MASH与低风险/无MASH的AUROC为0.847(95%CI 0.730-0.963)。

临床应用与阅片要点

  • 在日常阅片中,T1值或MRI-PDFF增高应提示MASH或纤维化MASH风险,建议结合临床进一步评估。
  • MRI-PDFF与T1均未见明确异常时,纤维化MASH可能性相对降低。
  • 使用IVIM参数时需注意其诊断效能未被充分报告,不宜单独作为排除或确诊依据。

局限性

  • 本研究为单中心研究。
  • 本研究为横断面设计。
  • 样本量有限。
  • 原文提出仍需进一步大规模、多中心研究验证其临床应用价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Liver biopsy is the gold standard for diagnosing metabolic dysfunction associated steatohepatitis (MASH). There is an unmet need for non-invasive tests to differentiate uncomplicated hepatic steatosis from steatohepatitis and fibrotic MASH.

OBJECTIVES: We aimed to evaluate the role of T1 relaxation time, MRI-PDFF (Proton density fat fraction), and IVIM (Intravoxel Incoherent motion) in detecting and differentiating MASH from non-MASH group of patients and fibrotic MASH from low-risk/absent MASH group.

MATERIAL & METHODS: We prospectively conducted a cross-sectional study of 64 patients with Metabolic dysfunction associated steatotic liver disease (MASLD) and reviewed MRI data from 46 patients who underwent liver biopsy. Dedicated sequences were performed using a 1.5 T MR scanner to derive liver MRI-PDFF, T1, and IVIM values (D-True diffusion coefficient, D*- pseudo diffusion coefficient, and f - perfusion fraction). The NASH CRN (Clinical Research Network) scoring system was used to categorize patients based on biopsy results. MR-derived data were compared with the biopsy results.

RESULTS: Median T1 values were significantly higher in patients with MASH than the non-MASH group (884.97 ms versus 698.59 ms; p = 0.0002, AUROC (95% CI) 0.828 (0.709-0.947)) and in fibrotic MASH versus low-risk/absent MASH group (870.48 ms versus 695.10 ms; p < 0.0001, AUROC (95% CI) 0.851 (0.742-0.961)). Median MRI-PDFF values were significantly higher in MASH patients compared to non-MASH patients (19.38% vs. 9.46%, p = 0.0004, AUROC (95% CI) 0.808 (0.657-0.937)) and in fibrotic MASH compared to low-risk/absent MASH (20.45% vs. 8.58%, p = 0.0001, AUROC (95% CI) 0.847 (0.730-0.963)). MASH patients showed significantly lower D* (p = 0.0167) and f (p = 0.0382) than the non-MASH group; fibrotic MASH patients had lower D (p = 0.042) and D* (p = 0.025) than the low-risk/absent MASH group. MRI T1 mapping and MRI-PDFF demonstrate good diagnostic accuracy for detecting biopsy-defined MASH and fibrotic MASH. Further large-scale, multicenter studies are required to establish their role in clinical practice and potentially help reduce reliance on liver biopsy.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Meharwade, Gupta, Goyal, et al. Quantitative MR biomarkers in identifying steatohepatitis and fibrosis associated with metabolic dysfunction associated liver disease-a single center cross-sectional study. Abdom Radiol (NY). 2026. PMID: 42429971. doi:10.1007/s00261-026-05676-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。